May 24, 2019 Last Updated 10:12 AM, May 22, 2019

Revisiting IL-2 biology and therapeutic prospects

Published in News
Read 482 times
Rate this item
(0 votes)

Interleukin-2 (IL-2) is one of the most important cytokines of adaptive immunity. It was first identified as a principal autocrine mitogenic factor for T cells, as well as being the first product of recombinand DNA technology to be used as immuno-boosting treatment for human experimentation in pathologies in which immune modulation was a promising therapeutic strategy (e.g. cancer or AIDS). However, its role in adaptive immune response, as it was later discovered, goes well beyond that of a "mere" aspecific growth factor for T cells. Quite soon, in fact, researcers had to deal with the baffling evidence that patients with autoimmune disease displayed low production of IL-2, while mouse models with compromised IL-2 signal axis developed autoimmune conditions, a puzzle that was clarified only when Tregs were discovered.  

In this review, Abul K. Abbas (a name which needs absolutely no introductions) and collegues revised the history, biology, genetics and the therapeutic approaches based on IL-2 known so far. 

Source: Science Immunology

Full text (for registered users)

Last modified on Monday, 26 November 2018 11:58
Login to post comments

Registered area

Thanks to the support of
merck serono biogen sanofi

Conferences & Courses

17° Corso CRNI Viva la differenza: sesso e neuroimmunologia

March 7-10, 2018 
Bergamo - Bergamo Science Center


Encefaliti Autoimmuni e Malattie Demielinizzanti Atipiche

16 febbraio 2018
Aula Magna Giorgio De Sandre


JNIInternational Brain Research Organization
Bringing Neuroscience to the World
JNIJournal of Neuroimmunology
Studies on all branches of neurosciences covering both research and clinical problems of neuroscientific interest.

This website or its third party tools use cookies, which are necessary to its functioning and required to achieve the purposes illustrated in the cookie policy. If you want to know more or withdraw your consent to all or some of the cookies, please refer to the cookie policy. By closing this banner, scrolling this page, clicking a link or continuing to browse otherwise, you agree to the use of cookies. To find out more about the cookies we use and how to delete them, see our Cookie Policy